Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

After age, sex, and disease duration were matched, the variables for which there was a statistical difference before were no longer significant (Additional file 1: Table S2).Characteristics of pSS patients with or without OAVariablepSS-OApSS-nOAp value1ORp value2n = 186n = 182Female (n, %)172(92.5)166(91.2)0.659Age (≥ 65 year) (n, %)71(38.2)41(22.5)0.0011.9650.009Disease duration (year) M (IQR)5(2 to 10)3(1 to 10)0.0341.0230.112Clinical manifestation (n, %) Dry mouth164(88.2)150(82.4)0.119 Dry eye134(72.8)121(66.9)0.215 Mouth ulcers52(28.0)37(20.3)0.088 Dental caries and dentures114(61.3)102(56.0)0.308 Swollen parotid gland20(10.8)20(11.0)0.942 Rash34(18.3)45(24.7)0.133 Renault phenomenon22(11.8)32(17.6)0.119 Joint pain108(58.1)54(29.7) < 0.0013.382 < 0.001 Fatigue35(18.8)43(23.6)0.260 ESSDAI score M (IQR)4(2 to 8)5(3 to 10)0.0060.9650.098ESSDAI domains (n, %) Constitutional1(0.5)1(0.5)1.000 Lymphadenopathy8(4.3)11(6.0)0.451 Glandular22(11.8)17(9.4)0.461 Articular24(12.9)17(9.4)0.279 Cutaneous5(2.7)13(7.1)0.0480.3590.057 Pulmonary35(18.8)42(23.5)0.278 Renal7(3.8)6(3.4)0.833 Muscular4(2.2)3(1.6)1.000 Peripheral nervous system6(3.2)11(6.0)0.199 Central nervous system0(0.0)1(0.5)0.495 Hematological109(58.6)123(67.6)0.075 Biological103(55.7)114(64.8)0.078Laboratory data Hemoglobin (g/L), x ± s119 ± 14.8115 ± 18.80.0301.0050.515 A/G1.3 ± 0.31.2 ± 0.30.0120.8470.796 Globulin (g/L), x ± s31.8 ± 7.534.5 ± 11.00.0080.9580.128 Albumin (g/L), x ± s38.2 ± 6.037.1 ± 5.10.058 K+ (mmol/L), x ± s3.8 ± 0.33.7 ± 0.40.0151.4040.263 Uric acid (umol/L), M (IQR)276(234.7 to 328.3)261(218.0 to 317.0)0.0301.0020.104 TC (mmol/L), M (IQR)4.6(4.0 to 5.3)4.5(3.7 to 4.9)0.0251.0150.670 TG (mmol/L), M (IQR)1.3(0.9 to 1.7)1.3(0.9 to 1.4)0.287 HDL (mmol/L), M (IQR)1.2(1.0 to 1.4)1.2(0.9 to 1.3)0.064 FBG (mmol/L), x ± s5.0 ± 1.04.9 ± 1.00.537 C3 (g/L), x ± s1.0 ± 0.20.9 ± 0.20.256 C4 (g/L), x ± s0.2 ± 0.10.19 ± 0.10.0044.2130.430 ANA positive (n, %)113(61.1)131(72.0)0.0270.6760.120 Anti-SSA positive (n, %)107(57.8)123(67.6)0.054 Anti-SSB positive (n, %)48(25.9)53(29.1)0.497 Anti-CCP positive (n, %)5(3.1)4(2.8)0.868 Increased RF (n, %)38(22.9)45(28.3)0.265 IgA (g/L), x ± s2.9 ± 1.43.3 ± 2.90.0490.8940.060 IgM (g/L), x ± s1.4 ± 1.41.6 ± 2.20.444 IgG (g/L), x ± s15.5 ± 6.016.7 ± 7.20.0351.0290.357 IgG4 (g/L), x ± s0.6 ± 1.80.5 ± 0.80.696 Increased CRP (n, %)15(8.3)23(13.3)0.133 Increased ESR (n, %)51(28.3)60(36.1)0.121 Decreased 25-(OH)D (n, %)28(17.5)18(12.5)0.226OA: osteoarthritis; A/G: albumin/globulin; UA: uric acid; TC: total cholesterol; TG: triglycerides; HDL: high density lipoprotein; FBG: fasting blood glucose; C3: complement 3; C4: complement 4; ANA: antinuclear antibodies; CCP: cyclic citrullinated peptide; RF: rheumatoid factor; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; 25-(OH) D: 25-hydroxy vitamin D

Source: Characteristics of pSS patients with or without OA. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were divided into groups according to whether complicated with OA or arthritis.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia

Study design awaiting verification · Journal of Orthopaedic Surgery and Research · 2023

Original publication title

Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia

Ronglin Gao; Jincheng Pu; Zhenzhen Wu; Jianping Tang; Xuan Wang

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In pSS patients with arthralgia, OA accounted for the majority. pSS patients with advanced age and more pronounced metabolic characteristics, such as elevated blood lipids and uric acid, was a key factor in groups at risk for OA. However, arthritis patients had higher rates of dry mouth and eye, higher disease activity, antibodies positive, and more organs damage. In the future, it may be necessary to be more cautious in the diagnosis of joint manifestations in pSS patients in order to make the appropriate treatments.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To identify primary Sjögren’s syndrome (pSS) patients with arthralgia at risk for osteoarthritis (OA) or arthritis.

Source: Objective

Abstract: What methods does the paper describe?

This study included 368 pSS patients admitted to a mono-centric from March 2010 to December 2020. Patients were divided into groups according to whether complicated with OA or arthritis. Data were analyzed to determine the differences in demographical characteristics, symptoms, and laboratory examination.

Source: Methods

Abstract: Results

The involvement of the OA joints was predominately knee and spine sites (including cervical and lumbar spine degeneration). When diagnosing arthritis, it was mainly peripheral symmetric polyarthritis, the most affected sites were the interphalangeal and metacarpophalangeal joints. There were significant differences in age, disease duration, uric acid (UA), and total cholesterol (TC) between pSS-OA and pSS-nOA patients (P < 0.050). Logistic regression analysis showed that age (OR = 1.965; P = 0.009) and joint pain (OR = 3.382; P < 0.001) were dangerous factors associated with OA.

Interestingly, although the level of UA, TC, and triglycerides (TG) was shown to be positive with OA, there was no statistical significance after the OR was computed in the four-cell table. In pSS-arthritis, EULAR Sjögren's syndrome disease activity index (ESSDAI) (P = 0.011), the frequency of joint pain (P < 0.001), and muscular involvement (P = 0.037) were higher than non-arthritis group. In pSS patients only presenting with joint pain, arthritis patients had higher ESSDAI and system involvements, but lower UA and TG levels compared with OA group (P < 0.050).

Source: Results

Abstract: Conclusion

In pSS patients with arthralgia, OA accounted for the majority. pSS patients with advanced age and more pronounced metabolic characteristics, such as elevated blood lipids and uric acid, was a key factor in groups at risk for OA. However, arthritis patients had higher rates of dry mouth and eye, higher disease activity, antibodies positive, and more organs damage. In the future, it may be necessary to be more cautious in the diagnosis of joint manifestations in pSS patients in order to make the appropriate treatments.

Source: Conclusion
Authors’ abstract

Objective

To identify primary Sjögren’s syndrome (pSS) patients with arthralgia at risk for osteoarthritis (OA) or arthritis.

Methods

This study included 368 pSS patients admitted to a mono-centric from March 2010 to December 2020. Patients were divided into groups according to whether complicated with OA or arthritis. Data were analyzed to determine the differences in demographical characteristics, symptoms, and laboratory examination.

Results

The involvement of the OA joints was predominately knee and spine sites (including cervical and lumbar spine degeneration). When diagnosing arthritis, it was mainly peripheral symmetric polyarthritis, the most affected sites were the interphalangeal and metacarpophalangeal joints. There were significant differences in age, disease duration, uric acid (UA), and total cholesterol (TC) between pSS-OA and pSS-nOA patients (P < 0.050). Logistic regression analysis showed that age (OR = 1.965; P = 0.009) and joint pain (OR = 3.382; P < 0.001) were dangerous factors associated with OA.

Interestingly, although the level of UA, TC, and triglycerides (TG) was shown to be positive with OA, there was no statistical significance after the OR was computed in the four-cell table. In pSS-arthritis, EULAR Sjögren's syndrome disease activity index (ESSDAI) (P = 0.011), the frequency of joint pain (P < 0.001), and muscular involvement (P = 0.037) were higher than non-arthritis group. In pSS patients only presenting with joint pain, arthritis patients had higher ESSDAI and system involvements, but lower UA and TG levels compared with OA group (P < 0.050).

Conclusion

In pSS patients with arthralgia, OA accounted for the majority. pSS patients with advanced age and more pronounced metabolic characteristics, such as elevated blood lipids and uric acid, was a key factor in groups at risk for OA. However, arthritis patients had higher rates of dry mouth and eye, higher disease activity, antibodies positive, and more organs damage. In the future, it may be necessary to be more cautious in the diagnosis of joint manifestations in pSS patients in order to make the appropriate treatments.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13018-023-03513-1.

Publication and source details

Original title: Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia

Ronglin Gao; Jincheng Pu; Zhenzhen Wu; Jianping Tang; Xuan Wang

Journal of Orthopaedic Surgery and Research · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.National Natural Science Foundation of China grant8167159881801601Tang Jianping Wang Xuan Natural Science Foundation of Shanghai grant20ZR1451400Tang Jianping Clinical research program of Tongji Hospital Tongji UniversityITJZD1909Tang Jianping Science and technology commission of Shanghai20Y11911600Wang Xuan Shanghai Sailing Program17YF1417200Wang Xuan

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T20:57:13.615462+00:00

DOI: 10.1186/s13018-023-03513-1 · PMC9841668